
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines Ltd is poised for significant growth, primarily driven by positive key opinion leader (KOL) insights favoring its lead product, Brukinsa, which is projected to achieve peak sales of approximately $7.1 billion due to its preference over competing BTK inhibitors for new patient starts. The company's sonrotoclax, recognized as the most advanced BCL2 inhibitor, demonstrates improved efficacy and safety profiles, with expectations of surpassing the performance of established treatments like venetoclax, potentially generating peak sales of around $3.4 billion. Furthermore, BeOne's strategic initiatives in physician outreach and competitive contracting are anticipated to bolster Brukinsa's growth trajectory, with forecasts of over 40% year-over-year revenue growth leading the company toward profitable operations and positive free cash flow by 2025.
Bears say
The financial outlook for BeOne Medicines Ltd appears negative due to several critical factors. There is a risk of slower adoption rates for its commercial products, combined with potential failures in ongoing pipeline initiatives, which could significantly impact revenue generation and fair value assessments. Furthermore, the company's substantial cash burn, heightened competition in the oncology sector, and perceived geopolitical risks exacerbate uncertainties surrounding its market potential and competitive positioning.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares